Study Questions Efficacy of New Alzheimer's Drug; Experts Cite Flawed Analysis Methods
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
A meta-analysis of seven Alzheimer's drugs, including Lecanemab, has questioned their clinical benefit, finding minimal impact on cognitive decline despite amyloid plaque removal, and noting safety risks like brain edema and hemorrhage. Experts suggest the study's methodology may obscure real treatment advancements.